Anaesthetic management of cytoreductive surgery followed by hyperthermic intrathoracic chemotherapy perfusion

Journal of Cardiothoracic Surgery

York A Zausig²  Bernhard M Graf²  Hans-Stefan Hofmann¹  Michael Ried¹  Christoph Kerscher² 

[1] Department of Cardiothoracic Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg 93042, Germany;Department of Anaesthesiology, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany

关键词: One lung ventilation;    Thoracic epidural analgesia;    Hyperthermic intrathoracic chemotherapy perfusion;    Cytoreductive surgery;    Anaesthetic management;   

Others  :  1152212
DOI  :  10.1186/1749-8090-9-125

 received in 2014-02-20, accepted in 2014-07-08,  发布年份 2014

【 摘 要 】

Background

Macroscopic cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion (HITHOC) is a new multimodal approach for selected patients with primary and secondary pleural tumors, which may provide the patient with better local tumor control and increased overall survival rate.

Methods

We present a single-center study including 20 patients undergoing cytoreductive surgery and HITHOC between September 2008 and April 2013 at the University Medical Center Regensburg, Germany. Objective of the study was to describe the perioperative, anaesthetic management with special respect to pain and complication management.

Results

Anaesthesia during this procedure is characterized by increased intrathoracic airway and central venous pressure, hemodynamic alterations and the risk of systemic hypo- and hyperthermia. Securing an adequate intravascular volume is one of the primary goals to prevent decreased cardiac output as well as pulmonary edema. Transfusion of packed red blood cells (PRBC) was necessary in seven of 20 (35%) patients. Only two patients (10%) showed an impairment of coagulation in postoperative laboratory analysis. Perioperative forced diuresis is recommended to prevent postoperative renal insufficiency. Supplementary thoracic epidural analgesia in 13 patients (65%) showed a significant reduction of post-operative pain compared with peroral administration of opioid and non-opioid analgesics.

Conclusion

This article summarizes important experiences of the anaesthesiological and intensive care management in patients undergoing HITHOC.

【 授权许可】

   
2014 Kerscher et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Yellin A, Simansky DA, Paley M, Refaely Y: Hyperthermic pleural perfusion with cisplatin: early clinical experience. Cancer 2001, 92:2197-2203.
• [2]De Bree E, van Ruth S, Baas P, Rutgers EJ, van Zandwijk N, Witkamp AJ, Zoetmulder FA: Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002, 121:480-487.
• [3]Van Ruth S, Baas P, Haas R, Rutgers E, Verwaal V, Zoetmulder FA: Cytoredictive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003, 10:176-182.
• [4]Piso P, Dahlke MH, Ghali N, Iesalnieks I, Loss M, Popp F, von Breitenbuch P, Agha A, Lang SA, Kullmann F, Schlitt HJ: Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies. Int J Colorectal Dis 2007, 22(11):1295-1300.
• [5]Refaely Y, Simansky DA, Paley M, Gottfried M, Yellin A: Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 2001, 72:366-370.
• [6]Ried M, Potzger T, Braune N, Neu R, Zausig Y, Schalke B, Diez C, Hofmann H-S: Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumors: perioperative management and clinical experience. Eur J Cardiothorac Surg 2013, 43(4):801-807.
• [7]Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ: Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006, 24(10):1561-1567.
• [8]Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135(3):620-626.
• [9]Dang A, Mansfield P, Ilsin B, Hightower C, Aravindan N, Rice D, Riedel B: Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei. J Cardiothorac Vasc Anesth 2007, 21:265-268.
• [10]Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaihof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF: ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary. Circulation 2007, 116(17):1971-1996.
• [11]Geldner G, Kelm M, Leschke M, Mertens E, Meyer C, Mössner J, Obertacke U, Schwenk W, Wappner F, Zwissler B: Präoperative Evaluation erwachsener Patienten vor elektiven, nicht, kardiochirurgischen Eingriffen. Gemeinsame Empfehlung der DGAI, DGI, DGCH. Anästh Intensivmed 2010, 11:S788-S796.
• [12]Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM: Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010, 27:999-1015.
• [13]González-Bayón L, González-Moreno S, Ortega-Pérez G: Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol 2006, 32(6):619-624.
• [14]Farivar AS, Louie BE, Aye RW, Horton MP, Vallières E: Extrapleural pneumonectomy for primary pleural mullerian tumor in a young woman. Ann Thorac Surg 2012, 93(1):e1-e2.
• [15]Sugarbaker PH, Chang D, Stuart OA: Hyperthermic intraoperative thoracoabdominal chemotherapy. Gastroenterol Res Pract 2012, 2012:623417.
• [16]Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PH: Hemodynamic and cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open “coliseum technique”. Ann Surg Oncol 2000, 7(4):296-300.
• [17]Kanakoudis F, Petrou A, Michaloudis D, Chortaria G, Konstantinidou A: Anaesthesia for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, oxygen consumption and delivery. Anaesthesia 1996, 51:1033-1036.
• [18]Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M: Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 2008, 63(4):389-395.
• [19]Raspe C, Piso P, Wiesenack C, Bucher M: Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol 2012, 25:348-355.
• [20]Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Londorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F, Danish Study Group on Perioperative Fluid Therapy: Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003, 238:641-648.
• [21]Zausig Y, Weigand M, Graf BM: Perioperatives Flüssigkeitsmanagement. Anaesthesist 2006, 53:371-390.
• [22]Licker M, de Perrot M, Spiliopoulos A, Robert J, Diaper J, Chevalley C, Tschopp J-M: Risk factors for acute lung injury after thoracic surgery for lung cancer. Anesth Analg 2003, 97:1558-1565.
• [23]Bräuer A, Perl T, Quintel M: Perioperative thermal management. Anaesthesist 2006, 55(12):1321-1339.
• [24]Putzu M, Casati A, Berti M, Pagliarini G, Fanelli G: Clinical complications, monitoring and management of perioperative mild hypothermia: anesthesiological features. Acta Biomed 2007, 78(3):163-169.
• [25]Scott EM, Buckland R: A systematic review of intraoperative warming to prevent postoperative complications. AORN J 2006, 83(5):1104. 1107–13
• [26]Frank SM, Fleisher LA, Breslow MJ, Higgins MS, Olson KF, Kelly S, Beattie C: Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events: a randomized clinical trial. JAMA 1997, 277:1127-1134.
• [27]Cafiero T, Di Iorio C, Di Minno RM, Sivolella G, Confuorto G: Noninvasive cardiac monitoring by aortic blood flow determination in patients undergoing hyperthermic intraperitoneal intraoperative chemotherapy. Minerva Anestesiol 2006, 72:207-215.
• [28]Schmidt C, Moritz S, Rath S, Grossmann E, Wiesenack C, Piso P, Graf BM, Bucher M: Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. J Clin Oncol 2009, 100:297-301.
• [29]Mustafa KY, Selig WM, Burhop KE, Minnear FL, Malik AB: Hyperthermia-induced pulmonary edema. J Appl Physiol 1986, 60(6):1980-1985.
• [30]Suzuki S, Hotchkiss JR, Takahashi T, Olson D, Adams AB, Marini JJ: Effect of core body temperature on ventilator-induced lung injury. Crit Care Med 2004, 32(1):144-149.
• [31]Ginsberg MD, Busto R: Combating hyperthermia in acute stroke: a significant clinical concern. Stroke 1998, 29(2):529-534.
• [32]Vujaskovic Z, Gillette SM, Powers BE, LaRue SM, Gillette EL, Borak TB, Scott RJ, Ryan TP, Colacchio TA: Effects of intraoperative hyperthermia on peripheral nerves: neurological and electrophysiological studies. Int J Hyperthermia 1994, 10(1):41-49.
• [33]Rusch VW, Niedzwiecki D, Tao Y, Menendez-Botet C, Dnistrian A, Kelsen D, Saltz L, Markman M: Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 1992, 10(6):1001-1006.
• [34]Ratto GB, Civalleri D, Esposito M, Spessa E, Alloisio A, De Cian F, Vannozzi MO: Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999, 117(4):759-765.
• [35]Ried M, Diez C, Neu R, Hofmann H-S: Kombinierte Technik der chirurgischen Zytoreduktion und hyperthermen intrathorakalen Chemotherapieperfusion. Z Herz-Thorax-Gefäßchir 2010, 24(5):277-284.
• [36]Sear JW: Kidney dysfunction in the postoperative period. Br J Anaesth 95(1):20-32. Epub 2004 Nov 5
• [37]Cooksley TJ, Haji-Michael P: Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). World J Surg Oncol 2011, 9:169.
• [38]Joshi GP, Bonnet F, Shah R, Wilkinson RC, Camu F, Fischer B, Neugebauer EA, Rawal N, Schug SA, Simanski C, Kehlet H: A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg 2008, 107(3):1026-1040. Review
• [39]Litz RJ, Bleyl JU, Frank M, Albrecht DM: Combined anesthesia procedures. Anaesthesist 1999, 48(6):359-372.
• [40]Handley GH, Silbert BS, Mooney PH, Schweitzer SA, Allen NB: Combined general and epidural anesthesia versus general anesthesia for major abdominal surgery: postanesthesia recovery characteristics. Reg Anesth 1997, 22(5):435-441.
• [41]Brodner G, Meissner A, Rolf N, Van Aken H: Thoracic epidural anesthesia–more than an anesthesia technique. Anaesthesist 1997, 46(9):751-762.